人参皂甙Rb1对高脂饮食诱导C57/BL6小鼠肥胖的预防作用及机制探讨
|
摘要
研究目的
肥胖指体内脂肪积累过多,是由于能量摄入大于消耗所致。肥胖是一种慢性疾病,同时也是心脑血管疾病、2型糖尿病、骨关节病、某些肿瘤等慢性病和社会心理障碍的重要危险因素,也是导致早死、致残、影响生命质量和增加各国财政负担的重要公共卫生问题。近几十年来,随着经济发展和生活方式变化,全球肥胖率呈现持续上升趋势,预防肥胖的流行已成为全球面临的最重大的公共卫生挑战。目前的肥胖综合干预治疗安全可靠,但是受到饮食、运动、静息式生活方式等多种综合因素影响,效果较难维持；而药物减肥对于身体的副作用较大或者尚不明确,且药物减肥与手术治疗都同样存在反弹的问题。寻找安全有效的减肥保健品成为一条可能的途径。
与此同时,在饮食诱导肥胖模型的研究中,人们发现某一特殊食物使一部分个体发展为肥胖。而另一部分吃相同食物的个体没有发生肥胖。因此,有人提出食物诱导肥胖抵抗假说：即致肥胖饮食在体内产生一种代偿反应,使机体能够预防肥胖的发生。据文献报道同一品系、同一批小鼠饲用相同的高脂饲料,其中部分发生肥胖,部分不发生肥胖,前者被称为肥胖倾向(obesity prone, OP),而后者被称为肥胖抵抗(obesity resistance, OR),具体机制尚不十分清楚。本文旨在通过探讨植物提取物单体对于肥胖小鼠的预防肥胖的作用及机制的同时,排除肥胖抵抗对于肥胖研究的影响.比较单体与饮食改变的作用效果强弱,为进一步开发预防肥胖的保健品提供依据。
人参(panax ginseng C. A. Meyer)是我国传统的名贵中药,具有大补元气、补气益肺、生津止渴、安神益智等功效,属五加科草本植物。中国古老的药学典籍《神农本草经》把人参列为上品,言其具有“主补五脏、安精神、定魂魄、止惊悸、明目、开心益智,久服有轻身延年之功效”。人参素有“百草药王之美称,应用于中医临床已有二千多年的历史,由于其具有广泛的药理作用和医疗用途,因而受到国内外众多学者的重视,人参许多新的生物活性也相继被发现。近年来,一些临床研究和动物实验表明人参和西洋参及其主要活性成分人参皂甙具有降低血糖,增加胰岛素敏感性,减轻体重,调节糖脂代谢的作用,但其作用机制并不十分清楚。有研究发现人参提取物能促进糖尿病小鼠脂肪组织PPARγ的mRNA和蛋白水平,其中人参皂甙Rb1经体外细胞实验证实作为PPARγ配体,通过上调PPARγ2, C/EBPα的表达促进脂肪细胞的脂肪形成,增加基础和胰岛素刺激的葡萄糖利用,同时抑制基础脂解。表明人参和人参皂甙抗糖尿病的作用可能与促进脂肪细胞分化,胰岛素敏感性和抑制基础脂解有关。此外,动物实验发现Rb1通过中枢NPY和外周CCK作用对高脂饮食诱导的肥胖小鼠有减轻体重和脂肪含量的作用。
本课题基于现今关于肥胖和肥胖抵抗的最新研究进展,用高脂、高能饲料制备符合临床特点的肥胖与肥胖抵抗型C57/BL6小鼠模型,研究Rb1对肥胖预防的效果,比较Rb1对于肥胖的作用与单纯改变饮食对于代谢和食欲的调节差异。进行为期3w的Rb1干预实验,观察小鼠进食量,体重变化以及血脂,血糖变化,并采用ELISA和实时荧光定量PCR技术,检测肥胖与肥胖抵抗型C57/BL6小鼠在Rb1干预后中枢和外周血的NPY以及PYY的水平,为进一步探讨人参皂甙Rb1的对于肥胖防治机制及功能性保健食品的开发提供实验依据。
研究方法
清洁级雄性健康野生型C57/BL6小鼠70只,体重(21.6g±1.3g),按体重排序后读取电脑随机数字表抽取8只作为空白对照组,剩余62只用于制备肥胖与肥胖抵抗型小鼠模型。空白对照组(N)：每鼠每天自由饮水及进食普通饲料,造模组进食高脂饲料连续12w后称量体重时,参考体重大于N组的平均体重+1.96倍标准差和大于正常体重的20%的标准,将体重最大的20只作为肥胖组(DIO)；肥胖抵抗组(DR)：参考体重小于C组的平均体重+1.0倍标准差,将体重最小的10只作为DR组,余弃除。小鼠自由进食,每天观察小鼠的一般状况、饮食变化、行为(自主活动、精神状态)变化、毛发变化,每天称量饲料,每周称量小鼠体重。造模完成后记录48小时各组小鼠的进食量和能量摄入量作为基础参考值。
造模12w后根据体重分为肥胖型小鼠、肥胖抵抗型小鼠和正常对照组,肥胖组抽取5只为继续高脂喂养组(HF),5只高脂饮食变为低脂普通饮食的饮食改变组(DC),余10只为Rb1干预组。于第13w开始时给予DIO和DR组小鼠Rb1腹腔注射,同时给予普通对照组10%的乙醇稀释液进行注射3w。
在注射3w结束时,小鼠禁食12h后,摘眼球取血,用于测定TC、TG、HDL、LDL、glucose, NPY和PYY水平；血取净后,立即进行解剖,留取左叶肝脏于10%福尔马林溶液中固定,用于病理检测；同时迅速分离下丘脑,取完整小肠和小肠生理盐水漂净后置于液氮中保存,用于NPY和NPY Y2以及PYY测定。3w内每日记录各组小鼠进食量,称取每只小鼠体重,观察小鼠变化。免疫荧光酶联免疫吸附法测定血清中NPY, PYY的表达水平。两步法实时荧光定量逆转录聚合酶链反应检测下丘脑组织和肠道组织的NPY,NPY Y2以及PYYmRNA表达。
选择SPSS 13.0软件行统计学分析,P<0.05被认为有统计学差异。
结果
l、高脂、高能饲料制备肥胖与肥胖抵抗小鼠模型建立
DR与DIO组体重有显著性差异,DR与N组体重无显著性差异,DIO与N组体重有显著性差异。
2、人参皂甙Rb1对肥胖与肥胖抵抗型C57/BL6小鼠体重和代谢的影响。
病理结果显示,HF组小鼠肝脏出现严重的脂肪变性,而其余各组的肝脏病理正常。DIO小鼠的能量摄入量高于其他各组,尽管DR组小鼠的进食量低于N组小鼠,但是其能量摄入量基本相当。Rb1进行干预治疗以后,DIO-Rb1组小鼠的体重在第1w内急剧下降,后2w下降速率降低趋于平稳,基本维持在跟饮食组小鼠减重后的水平。DC组小鼠的体重3w内也下降,第1w内的降低速率最大,后平稳的下降。
空腹血糖结果显示：与普通对照组相比,HF组与DC组的血糖与之有差异,其余各组均无显著性差异；与高脂组相比,各组血糖均有显著性差异；血脂结果显示：与N组相比,DIO-Rb1组的TCH和HDL与之有统计学差异,DR-Rb1组的HDL和LDL与之有统计学差异,HF组的TCH和HDL与之有统计学差异；与DIO-Rb1组相比,N组和DR-Rb1组的TCH和HDL与之有统计学差异,DR-Rb1组的TCH和LDL与有统计学差异；与HF组相比,各组的HDL与之均有差异,N, DIO-Rb1, DC组的TCH与之有统计学差异,DR-Rb1的LDL与之又统计学差异(P<0.05)。
3、血清NPY, PYY在人参皂甙Rb1治疗饮食诱导肥胖与肥胖抵抗型小鼠中的表达。
DIO-Rb1组的NPY值与DC和HF组相比有统计学差异,使用Rb1注射的两组与N组之间无统计学差异,其余各组之间无统计学差异；除DIO-Rb1以外,N组PYY值与其余各组都有统计学差异,N组与DIO-Rb1组跟HF之间有统计学差异,与DIO-Rb1组相比,DR-Rb1, DC, HF组的PYY值都与之有统计学差异(P<0.05)。
4、下丘脑NPY, NPY Y2的mRNA,小肠PYY的mRNA在饮食诱导肥胖与肥胖抵抗型小鼠中的表达。
N, DIO-Rb1, DR-Rb1, DC组下丘脑的NPY mRNA水平明显低于HF组,这四组间没有显著性差异(P<0.05)；N, DIO-Rb1, DR-Rb1, DC组下丘脑的NPY-Y2 mRNA水平与HF相比有显著性差异,但是只有DIO-Rb1组的水平低于HF组,其他各组均高于HF组。在小肠内PYY mRNA的水平来看,N, DIO-Rb1, DR-Rb1, DC各组显著低于FHF组(P<0.05),其余各组间没有统计学差异。
结论
1.用高脂高能饲料成功制备肥胖与肥胖抵抗型小鼠模型。
2. Rb1腹腔注射可以对肥胖小鼠起到降低体重,改善血糖的作用,对血脂的改变主要体现在Tch和HDL水平上。Rb1的作用体现在第1w内的迅速将体重作用上,小鼠的进食量和能量摄取均再第1w内显著下降
3.Rb1通过提高血清的PYY水平,抑制了下丘脑NPY Y2的mRNA表达,从而降低了血清NPY水平,降低了下丘脑NPY mRNA表达,进而抑制了小鼠的食欲,起到了降低体重的作用。
4.Rb1腹腔给药的效果在血脂改变上与饮食改变相比无显著性差异,但是在血糖以及肠道—中枢食欲调节上有显著性差异。
Aims
Obesity is a major predisposing factor for cancer, type II diabetes, hypertension and coronary heart diseases with their enormous costs both socially and financially. Therefore, there is a pressing demand to research the mechanism of obesity so that effective treatment regimes to deal with its rising prevalence may be devised. It is well believed that energy accumulation can lead to obesity, and the high-fat and high-energy food can especially easily complete the task. However, in both rodents and humans, some become obese while others remain lean when raised the same high-fat and high-energy diet. The previous work has shown that when C57/BL6 mice are fed a high fat diet some mice develop obesity whist others remain lean. This has also been shown in early studies in rats fed a palatable high fat/high sugar diet. The study on this point has showed interesting results on their difference on appetite control system. In the central neural regulatory systems, neuropeptide Y plays an important role in appetite and energy balance. NPY consists of 36 ami no acids, and is a powerful neurochemical stimulator in feeding. PYY is a member of the pancreatic polypeptide family whose structure and function is related to NPY. PYY is mainly secreted from the endocrine L cells of the gastrointestinal tract and is related into the blood stream in response to the ingestion of food, especially fat. PYY has a high affinity for Y2 receptors, and upon binding can inhibit food intake via the hypothalamic arcuate nucleus.
Ginsenosides, the main component of Panax ginseng root, has been reported to show several pharmacological actions on the peripheral Metabolism of glucose and lipid and on endocrine secretion. Recent studies showed that administration of Panaxoside Rbl in high fat diet group reduced the body weight, total food intake, fat content, serum ieptin and NO to a level equal or below the normal diet group in SD rats. In vitro study revealed that Rbl promoted adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPαgene expression. Little is known about the specific effect and feature of Rbl on anti-obesity in DIO and DR mice, especially compared with diet pattern change, as well as its effect with time change. Besides, the literature revealed that Rbl was a suppressor in central modulation of feeding in the rat through NPY pathways. Our study aimed to find the change of peripheral NPY and PYY between groups.
Ginsenoside Rbl, the main component of ginsenosides, have been reported to show a variety of efficacies such as anticancer, antihypertension, antidiabetes, and antinociception. In the present study, the anti-obesity effect of Ginseng Panaxosides Rb1 on diet-induced obese mice were evaluated.
Methods
Seventy C57/BL6 male mice were randomly divided into chow diet (N, n=8) group and high fat diet group (n=62). After fed with high fat and energy diet for 12 weeks, the mice were divided into two groups, including an obesity group (DIO, n=20) and obesity-resistant group (DR, n=10) according to the highest and lowest weight gain, with other mice discarded. Obesity group was then subgrouped into DIO-Rb1 injection group (n=10), diet change to normal group (DC,n=5) and no intervention group (HF,n=5). Intraperitoneal injection of Rb-1 was received daily by mice in DIO-Rb1 and DR group for 3 weeks. Body weight and food intake were observed, and fasting blood glucose, lipids was examined by biochemical analyzer. In addition, we also determined the secretion and expression of neuropeptide Y (NPY), Y2 receptor, and Peptide YY (PYY) by enzyme linked immunosorbent assay (ELISA) and real-time RT-PCR.
Results
Effects of Rbl on the body weight and food intake
Body weight is a gold standard of obese. So we firstly investigated the effect of Rbl on body weight of obese mice. After fed with high-fat diet for 12 weeks, the body weight of diet-induced obese (DIO) mice was significant increase. However, after treatment with Rb1 for 3 weeks, the body weight of DIO-Rb1 group was obvious decrease when compared with that in DIO group. In addition, we also detected the food intake after treatment with Rb1. We found that food intake was also decrease in DIO-Rbl group as compared with that in DIO group.
Effects of Rbl on the blood glucose and lipids
The blood glucose and lipids are also important indices of obese. Thus, we also detected the effects of Rb1 on fasting blood glucose and lipids. After fed with high-fat diet for 12 weeks, the fasting blood glucose and total cholesterol (TC) of DIO mice were significant increase. Whereas, after treatment with Rb1 for 3 weeks, the fasting blood glucose and total cholesterol of DIO-Rb1 group were obvious decrease when compared with those in DIO group. Additionally, there was no significant difference in triglyceride(TG) among three groups.
Effects of Rb1 on the serum levels of PYY and NPY
It is well known that PYY and NPY are involved in the obese, so we next measured the serum levels of PYY and NPY to explore the possible action mechanisms of Rb1. As shown in table 4, after fed with high-fat diet for 12 weeks, the serum PYY of DIO mice was significant decrease. Rb1 could inhibit the decreasing of serum PYY of DIO mice. On the contrary, after fed with high-fat diet for 12 weeks, the serum NPY of DIO mice was significant increase. Rb1 could reverse the increasing of serum NPY of DIO mice.
Effects of Rb1 on the mRNA levels of NPY, NPY-2R and PYY
The mRNA levels of NPY in hypothalamus were significantly lower in N and DIO-Rb1 groups than that in DIO group (P<0.05). Similar pattern was observed in NPY-2R level. Rb1 could reverse the increasing of NPY-2R expression to normal level. The mRNA level of PYY in intestine tract in DIO group was lower than that in any other group
Conclusions
Taken together, our results indicate that the ginsenoside Rb1 may be useful in the treatment of obesity via modifying the serum content and mRNA expression of NPY, Y2 receptor and PYY.
肥胖指体内脂肪积累过多,是由于能量摄入大于消耗所致。肥胖是一种慢性疾病,同时也是心脑血管疾病、2型糖尿病、骨关节病、某些肿瘤等慢性病和社会心理障碍的重要危险因素,也是导致早死、致残、影响生命质量和增加各国财政负担的重要公共卫生问题。近几十年来,随着经济发展和生活方式变化,全球肥胖率呈现持续上升趋势,预防肥胖的流行已成为全球面临的最重大的公共卫生挑战。目前的肥胖综合干预治疗安全可靠,但是受到饮食、运动、静息式生活方式等多种综合因素影响,效果较难维持；而药物减肥对于身体的副作用较大或者尚不明确,且药物减肥与手术治疗都同样存在反弹的问题。寻找安全有效的减肥保健品成为一条可能的途径。
与此同时,在饮食诱导肥胖模型的研究中,人们发现某一特殊食物使一部分个体发展为肥胖。而另一部分吃相同食物的个体没有发生肥胖。因此,有人提出食物诱导肥胖抵抗假说：即致肥胖饮食在体内产生一种代偿反应,使机体能够预防肥胖的发生。据文献报道同一品系、同一批小鼠饲用相同的高脂饲料,其中部分发生肥胖,部分不发生肥胖,前者被称为肥胖倾向(obesity prone, OP),而后者被称为肥胖抵抗(obesity resistance, OR),具体机制尚不十分清楚。本文旨在通过探讨植物提取物单体对于肥胖小鼠的预防肥胖的作用及机制的同时,排除肥胖抵抗对于肥胖研究的影响.比较单体与饮食改变的作用效果强弱,为进一步开发预防肥胖的保健品提供依据。
人参(panax ginseng C. A. Meyer)是我国传统的名贵中药,具有大补元气、补气益肺、生津止渴、安神益智等功效,属五加科草本植物。中国古老的药学典籍《神农本草经》把人参列为上品,言其具有“主补五脏、安精神、定魂魄、止惊悸、明目、开心益智,久服有轻身延年之功效”。人参素有“百草药王之美称,应用于中医临床已有二千多年的历史,由于其具有广泛的药理作用和医疗用途,因而受到国内外众多学者的重视,人参许多新的生物活性也相继被发现。近年来,一些临床研究和动物实验表明人参和西洋参及其主要活性成分人参皂甙具有降低血糖,增加胰岛素敏感性,减轻体重,调节糖脂代谢的作用,但其作用机制并不十分清楚。有研究发现人参提取物能促进糖尿病小鼠脂肪组织PPARγ的mRNA和蛋白水平,其中人参皂甙Rb1经体外细胞实验证实作为PPARγ配体,通过上调PPARγ2, C/EBPα的表达促进脂肪细胞的脂肪形成,增加基础和胰岛素刺激的葡萄糖利用,同时抑制基础脂解。表明人参和人参皂甙抗糖尿病的作用可能与促进脂肪细胞分化,胰岛素敏感性和抑制基础脂解有关。此外,动物实验发现Rb1通过中枢NPY和外周CCK作用对高脂饮食诱导的肥胖小鼠有减轻体重和脂肪含量的作用。
本课题基于现今关于肥胖和肥胖抵抗的最新研究进展,用高脂、高能饲料制备符合临床特点的肥胖与肥胖抵抗型C57/BL6小鼠模型,研究Rb1对肥胖预防的效果,比较Rb1对于肥胖的作用与单纯改变饮食对于代谢和食欲的调节差异。进行为期3w的Rb1干预实验,观察小鼠进食量,体重变化以及血脂,血糖变化,并采用ELISA和实时荧光定量PCR技术,检测肥胖与肥胖抵抗型C57/BL6小鼠在Rb1干预后中枢和外周血的NPY以及PYY的水平,为进一步探讨人参皂甙Rb1的对于肥胖防治机制及功能性保健食品的开发提供实验依据。
研究方法
清洁级雄性健康野生型C57/BL6小鼠70只,体重(21.6g±1.3g),按体重排序后读取电脑随机数字表抽取8只作为空白对照组,剩余62只用于制备肥胖与肥胖抵抗型小鼠模型。空白对照组(N)：每鼠每天自由饮水及进食普通饲料,造模组进食高脂饲料连续12w后称量体重时,参考体重大于N组的平均体重+1.96倍标准差和大于正常体重的20%的标准,将体重最大的20只作为肥胖组(DIO)；肥胖抵抗组(DR)：参考体重小于C组的平均体重+1.0倍标准差,将体重最小的10只作为DR组,余弃除。小鼠自由进食,每天观察小鼠的一般状况、饮食变化、行为(自主活动、精神状态)变化、毛发变化,每天称量饲料,每周称量小鼠体重。造模完成后记录48小时各组小鼠的进食量和能量摄入量作为基础参考值。
造模12w后根据体重分为肥胖型小鼠、肥胖抵抗型小鼠和正常对照组,肥胖组抽取5只为继续高脂喂养组(HF),5只高脂饮食变为低脂普通饮食的饮食改变组(DC),余10只为Rb1干预组。于第13w开始时给予DIO和DR组小鼠Rb1腹腔注射,同时给予普通对照组10%的乙醇稀释液进行注射3w。
在注射3w结束时,小鼠禁食12h后,摘眼球取血,用于测定TC、TG、HDL、LDL、glucose, NPY和PYY水平；血取净后,立即进行解剖,留取左叶肝脏于10%福尔马林溶液中固定,用于病理检测；同时迅速分离下丘脑,取完整小肠和小肠生理盐水漂净后置于液氮中保存,用于NPY和NPY Y2以及PYY测定。3w内每日记录各组小鼠进食量,称取每只小鼠体重,观察小鼠变化。免疫荧光酶联免疫吸附法测定血清中NPY, PYY的表达水平。两步法实时荧光定量逆转录聚合酶链反应检测下丘脑组织和肠道组织的NPY,NPY Y2以及PYYmRNA表达。
选择SPSS 13.0软件行统计学分析,P<0.05被认为有统计学差异。
结果
l、高脂、高能饲料制备肥胖与肥胖抵抗小鼠模型建立
DR与DIO组体重有显著性差异,DR与N组体重无显著性差异,DIO与N组体重有显著性差异。
2、人参皂甙Rb1对肥胖与肥胖抵抗型C57/BL6小鼠体重和代谢的影响。
病理结果显示,HF组小鼠肝脏出现严重的脂肪变性,而其余各组的肝脏病理正常。DIO小鼠的能量摄入量高于其他各组,尽管DR组小鼠的进食量低于N组小鼠,但是其能量摄入量基本相当。Rb1进行干预治疗以后,DIO-Rb1组小鼠的体重在第1w内急剧下降,后2w下降速率降低趋于平稳,基本维持在跟饮食组小鼠减重后的水平。DC组小鼠的体重3w内也下降,第1w内的降低速率最大,后平稳的下降。
空腹血糖结果显示：与普通对照组相比,HF组与DC组的血糖与之有差异,其余各组均无显著性差异；与高脂组相比,各组血糖均有显著性差异；血脂结果显示：与N组相比,DIO-Rb1组的TCH和HDL与之有统计学差异,DR-Rb1组的HDL和LDL与之有统计学差异,HF组的TCH和HDL与之有统计学差异；与DIO-Rb1组相比,N组和DR-Rb1组的TCH和HDL与之有统计学差异,DR-Rb1组的TCH和LDL与有统计学差异；与HF组相比,各组的HDL与之均有差异,N, DIO-Rb1, DC组的TCH与之有统计学差异,DR-Rb1的LDL与之又统计学差异(P<0.05)。
3、血清NPY, PYY在人参皂甙Rb1治疗饮食诱导肥胖与肥胖抵抗型小鼠中的表达。
DIO-Rb1组的NPY值与DC和HF组相比有统计学差异,使用Rb1注射的两组与N组之间无统计学差异,其余各组之间无统计学差异；除DIO-Rb1以外,N组PYY值与其余各组都有统计学差异,N组与DIO-Rb1组跟HF之间有统计学差异,与DIO-Rb1组相比,DR-Rb1, DC, HF组的PYY值都与之有统计学差异(P<0.05)。
4、下丘脑NPY, NPY Y2的mRNA,小肠PYY的mRNA在饮食诱导肥胖与肥胖抵抗型小鼠中的表达。
N, DIO-Rb1, DR-Rb1, DC组下丘脑的NPY mRNA水平明显低于HF组,这四组间没有显著性差异(P<0.05)；N, DIO-Rb1, DR-Rb1, DC组下丘脑的NPY-Y2 mRNA水平与HF相比有显著性差异,但是只有DIO-Rb1组的水平低于HF组,其他各组均高于HF组。在小肠内PYY mRNA的水平来看,N, DIO-Rb1, DR-Rb1, DC各组显著低于FHF组(P<0.05),其余各组间没有统计学差异。
结论
1.用高脂高能饲料成功制备肥胖与肥胖抵抗型小鼠模型。
2. Rb1腹腔注射可以对肥胖小鼠起到降低体重,改善血糖的作用,对血脂的改变主要体现在Tch和HDL水平上。Rb1的作用体现在第1w内的迅速将体重作用上,小鼠的进食量和能量摄取均再第1w内显著下降
3.Rb1通过提高血清的PYY水平,抑制了下丘脑NPY Y2的mRNA表达,从而降低了血清NPY水平,降低了下丘脑NPY mRNA表达,进而抑制了小鼠的食欲,起到了降低体重的作用。
4.Rb1腹腔给药的效果在血脂改变上与饮食改变相比无显著性差异,但是在血糖以及肠道—中枢食欲调节上有显著性差异。
Aims
Obesity is a major predisposing factor for cancer, type II diabetes, hypertension and coronary heart diseases with their enormous costs both socially and financially. Therefore, there is a pressing demand to research the mechanism of obesity so that effective treatment regimes to deal with its rising prevalence may be devised. It is well believed that energy accumulation can lead to obesity, and the high-fat and high-energy food can especially easily complete the task. However, in both rodents and humans, some become obese while others remain lean when raised the same high-fat and high-energy diet. The previous work has shown that when C57/BL6 mice are fed a high fat diet some mice develop obesity whist others remain lean. This has also been shown in early studies in rats fed a palatable high fat/high sugar diet. The study on this point has showed interesting results on their difference on appetite control system. In the central neural regulatory systems, neuropeptide Y plays an important role in appetite and energy balance. NPY consists of 36 ami no acids, and is a powerful neurochemical stimulator in feeding. PYY is a member of the pancreatic polypeptide family whose structure and function is related to NPY. PYY is mainly secreted from the endocrine L cells of the gastrointestinal tract and is related into the blood stream in response to the ingestion of food, especially fat. PYY has a high affinity for Y2 receptors, and upon binding can inhibit food intake via the hypothalamic arcuate nucleus.
Ginsenosides, the main component of Panax ginseng root, has been reported to show several pharmacological actions on the peripheral Metabolism of glucose and lipid and on endocrine secretion. Recent studies showed that administration of Panaxoside Rbl in high fat diet group reduced the body weight, total food intake, fat content, serum ieptin and NO to a level equal or below the normal diet group in SD rats. In vitro study revealed that Rbl promoted adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPαgene expression. Little is known about the specific effect and feature of Rbl on anti-obesity in DIO and DR mice, especially compared with diet pattern change, as well as its effect with time change. Besides, the literature revealed that Rbl was a suppressor in central modulation of feeding in the rat through NPY pathways. Our study aimed to find the change of peripheral NPY and PYY between groups.
Ginsenoside Rbl, the main component of ginsenosides, have been reported to show a variety of efficacies such as anticancer, antihypertension, antidiabetes, and antinociception. In the present study, the anti-obesity effect of Ginseng Panaxosides Rb1 on diet-induced obese mice were evaluated.
Methods
Seventy C57/BL6 male mice were randomly divided into chow diet (N, n=8) group and high fat diet group (n=62). After fed with high fat and energy diet for 12 weeks, the mice were divided into two groups, including an obesity group (DIO, n=20) and obesity-resistant group (DR, n=10) according to the highest and lowest weight gain, with other mice discarded. Obesity group was then subgrouped into DIO-Rb1 injection group (n=10), diet change to normal group (DC,n=5) and no intervention group (HF,n=5). Intraperitoneal injection of Rb-1 was received daily by mice in DIO-Rb1 and DR group for 3 weeks. Body weight and food intake were observed, and fasting blood glucose, lipids was examined by biochemical analyzer. In addition, we also determined the secretion and expression of neuropeptide Y (NPY), Y2 receptor, and Peptide YY (PYY) by enzyme linked immunosorbent assay (ELISA) and real-time RT-PCR.
Results
Effects of Rbl on the body weight and food intake
Body weight is a gold standard of obese. So we firstly investigated the effect of Rbl on body weight of obese mice. After fed with high-fat diet for 12 weeks, the body weight of diet-induced obese (DIO) mice was significant increase. However, after treatment with Rb1 for 3 weeks, the body weight of DIO-Rb1 group was obvious decrease when compared with that in DIO group. In addition, we also detected the food intake after treatment with Rb1. We found that food intake was also decrease in DIO-Rbl group as compared with that in DIO group.
Effects of Rbl on the blood glucose and lipids
The blood glucose and lipids are also important indices of obese. Thus, we also detected the effects of Rb1 on fasting blood glucose and lipids. After fed with high-fat diet for 12 weeks, the fasting blood glucose and total cholesterol (TC) of DIO mice were significant increase. Whereas, after treatment with Rb1 for 3 weeks, the fasting blood glucose and total cholesterol of DIO-Rb1 group were obvious decrease when compared with those in DIO group. Additionally, there was no significant difference in triglyceride(TG) among three groups.
Effects of Rb1 on the serum levels of PYY and NPY
It is well known that PYY and NPY are involved in the obese, so we next measured the serum levels of PYY and NPY to explore the possible action mechanisms of Rb1. As shown in table 4, after fed with high-fat diet for 12 weeks, the serum PYY of DIO mice was significant decrease. Rb1 could inhibit the decreasing of serum PYY of DIO mice. On the contrary, after fed with high-fat diet for 12 weeks, the serum NPY of DIO mice was significant increase. Rb1 could reverse the increasing of serum NPY of DIO mice.
Effects of Rb1 on the mRNA levels of NPY, NPY-2R and PYY
The mRNA levels of NPY in hypothalamus were significantly lower in N and DIO-Rb1 groups than that in DIO group (P<0.05). Similar pattern was observed in NPY-2R level. Rb1 could reverse the increasing of NPY-2R expression to normal level. The mRNA level of PYY in intestine tract in DIO group was lower than that in any other group
Conclusions
Taken together, our results indicate that the ginsenoside Rb1 may be useful in the treatment of obesity via modifying the serum content and mRNA expression of NPY, Y2 receptor and PYY.
引文
[1]葛可佑.90年代中国人群的饮食与营养状况(1992年全国营养调查) (第1卷)[M].北京：人民卫生出版社,1995：424.
[2]中国肥胖问题工作组数据总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指教和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-1.
[3]武阳丰,周北凡,廊寿淇,等.我国中年人群超重率和肥胖率的现状及发展趋势[J].中华流行病学杂志,2002,23(1)：11-15.
[4]Kissebah AH, Krakower GR.Regional adiposity and mortality[J]. Physiol Rev,1994,74:761-811.
[5]傅祖植.开展与肥胖相关课题的研究是新世纪的迫切任务[J].中华内分泌代谢杂志,2000,16： 65-66.
[6]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29(2)：153-156.
[7]Levin BE, Richard EK. Defense of differing body weight set points in diet-induced obese and resistant rats[J]. Am J Physiol,1998,274:r412-419.
[8]马健.神经肽Y与肥胖的研究进展[J].心血管病学进展,2004,(增刊)：91-93.
[9]Levin BE, Dunn-Meynell AA, Balkan B, et al.Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats[J]. Am J Physiol,1997,273(2 Pt 2):R725-30.
[10]Mizuno TM, Kleopoulos SP, Bergen HT,et al.Hypothalamic pro-opiomel anocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin[J].Diabetes,1998, 47(4):696.
[11]罗辉.人参皂甙的生物特性及其临床应用研究[J].井冈山学院学报,2006,8：79-82.
[12]Shang WB, Yang Y, Jiang BR, et al.Ginsenoside Rbl promotes adipogenesis in 3T3-L1 cells by enhancing PPARy2 and C/EBPa gene expression[J].Life Sciences,2007,80:618-625.
[13]Kim JH, Young HY, Kang SA. Ginsenoside Rbl as a suppressor in central modulation of feeding in rat[J]. Appetite,2007,49:303.
[1]何晓烨,石风英.高脂饮食在诱导小鼠肥胖及肥胖抵抗中的作用[J].中国临床康复,2002,6：60-61.
[2]孙志,张中成,刘志诚.营养性肥胖动物模型的实验研究[J].中国药理学通报,2002,18(4)：466-467.
[3]王舒然,麻微微,赵丹,等.高脂饮食诱导肥胖与肥胖抵抗动物模型建立[J].中国公共卫生,2007,2(7)：774-775.
[4]Xu-Feng H. Yinghua Y, Yulin L, et al. Ventromedial Hypothalamic NPY Y2 Receptor in the Maintenance of Body Weight in Diet-Induced Obesity in Mice. Neurochem Res[J]. ISSN:1573-6903 (Online).
[5]Richard SS. Shiying W, Anne P, et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice[J].Proc Natl Acad Sci,1998,95:4061-4065.
[6]王重建,杨年红,许明佳.高脂饮食诱导小鼠肥胖易感性差异的研究[J].华中科技大学学报(医学版),2005,1：65.
[7]Levin BE. Metabolic features of diet-induced obesity without hyperphagiain young rats[J]. Am J Physiol,1986,251:433.
[8]Barry EL, Joseph T, Susan H, et al. Resistance to diet-induced obesity:food intake, pancreatic sympathetic tone and insulin[J]. Am J Physiol,1987,252:471-478.
[9]David BW, Carol NB, Deborah LM, et al. Diet obesity in nine inbred mouse strains[J]. Am J Phvsiol,1992,262:1025-1032.
[10]王从容,谭健,杨锡让.高脂饲料诱发小鼠肥胖模型的建立及间接推测体脂法[J].北京体育大学学报,1994,17(3)：20-23.
[11]薛长勇.肥胖和膳食的关系及其措食治疗[J].现代康复,2001,5(9上)：10-11.
[12]FORET JP POSTO WSC.饮食、运动和生活方式变垂在肥胖型糖尿病治疗中的作用[J].现代康复,2001,5(7上)：24-26.
[13]Joseph AM, Yakubu, Lin D,et al. Skeletal musle composition in dietary obesity-susceptible and dietary obesity-resistant rats[J]. Am J Physiol,1992,262:R684-R688.
[14]Sam C, Brent G, Fatima Y, et al. Metabolic differences between obesity-prone and obesity-resistant rats[J]. Am J Physiol,1990,259:R1103-1110.
[15]Thomas JL, Ariel B, Mark D, el al. Plasma growth hormone secretion is impaired in obesity-prone rats before onset of diet-induced obesity[J]. Am J Physiol,1998,275:E6-11.
[16]Beauville M, HarantT I, Crampes F, et al. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine respone[J].Am J Physiol,1992,263:E467-472.
[17]刘庆春,刘晌烨,杜金赞,等.短期内建立营养性肥胖动物模型的实验研究[J].武警医学,2004,15：371-372.
[18]马爽,刘莉,李岩溪,等.肥胖和肥胖抵抗小鼠脂肪组织PPAR7和aP2基因表达的研究[J].卫生研究，2009,3：163-165.
[19]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002.3：153-156.
[1]罗辉.人参皂甙的生物特性及其临床应用的研究[J].井冈山学院学报(自然科学),2006,8：79-82.
[2]丛登云,宋长春,徐景达.西洋参叶中20(S)-人参皂甙Rh2和人参皂甙Rh3的分离和鉴定[J].中国药学杂志,2000，35(2)：82.
[3]Kim JH, Young HY, Kang SA.Ginsenoside Rbl as a suppressor in central modulation of feeding in rat[J]. Appetite,2007,49:303.
[4]Shang WB, Yang Y, Jiang BR, et al.Ginsenoside Rbl promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expression[J]. Life Sciences,2007,80:618-625.
[5]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29(3)：153-156.
[6]Zhang YY, Proenca R, MaffeiM, et al. Positional cloning of themouse obese gene and its human homologue[J].Nature,1994,372:425-432.
[7]刘荣,孙长颢,王舒然,等.饮食诱导肥胖抵抗和饮食诱导肥胖小鼠的对比研究[J].中国公共卫生,2003,19(5)：563-565.
[8]刘荣,孙长颢,李颖,等.饮食诱导肥胖抵抗和肥胖小鼠血中激素水平的比较[J].卫生研究,2003,32(3)：212-214.
[9]Chang S, Graham B, Yakubu F, et al.Metabolic differences between obesity-prone and obesity resistant rats[J].Am J Physiol,1990,259:R11O3.
[10]Terham R L, Cowley M A, Small C J, et al.Gut hormone PYY3-36 physiologicaily inhibits food intake[J].Nature,2002,418:650.
[11]Cowley M A, Smart J L, Rubinstein M,et al.Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus[J]. Nature,2001,411:480.
[12]Akazato M,M urakami N,Date Y, et al. A role for ghrelin in the central regulation of feeding[J]. Nature,2001,409:194.
[13]Pagliassotti MJ,Shahrokhi KA, Hill JO. Skeletal muscle glucose Metabolism in obesity-prone and obesity-resistant rats[J]. Am J Physiol,1993,264:R1224.
[14]Abou M J,Yakubu F,Lin D, et al. Skeletal muscle composition in dietary obesity-susceptible and dietary obesity-resistant rats[J]. Am J Physiol,1992,262:R684.
[15]Weigle D S,Levin B E.Defective dietary induction of uncoupling protein 3 in skeletal muscle of obesity-prone rats[J].Obesity Res,2000,8:385.
[16]Day cp.Non-alcoholic stentohepatisis (NASH):Where are we now and where are we going [J]. Gut,2002,50:585-586.
[17]薛广波.现代疾病预防学[M].北京：人民军医出版社,1996：10.
[18]赵飞,王玉玮,刘心洁,等.高脂诱导肥胖与肥胖抵抗小鼠血糖、血脂、瘦素及胰岛素敏感性比较[J].中国儿童保健杂志,2004,12(6)：517-519.
[19]施万英,徐甲芬,姚兴家,等.高脂饮食对肥胖倾向和肥胖抵抗小鼠血清脂质和TNF-α水平的影响[J].中国医科大学学报,33(4)：330-332.
[20]Dobrian AD, Davies IJ, Prewitt RL, et al. Development of hypertension in a rat model of diet-induced obesity[J]. Hypertension,2000,35(4):1009-1015.
[1]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29：153-156.
[2]张贝,李成江.PYY与肥胖[J].国外医学内分泌学分册,2005,25(suppl)：6-8.
[3]Batterham RL,Small CJ,Cowley MA,et al.Gut hormone PYY(3-36) physiologically inhibit food intake[J].Nature,2002,418:650-654.
[4]Sainsbury A, Schwarzer C, Couzens M,et al.Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice[J].Proc Natl Acad Sci USA,2002,99(13): 8938-8943.
[5]Batterham RL, Cowley MA, Small CJ, et al.Gut hormone PYY(3-36) physiologically inhibits food intake [J].Nature,2002,418(6898):650-4.
[6]Baskin DG, Breininger JF, Schartz MW. Leptin receptor mRNA identifiers a sub-population of neuropeptide Y neurons activated by fasting in rAt hypothatamus[J].Diabetes,1999,48(4):828-833.
[7]Hakasson ML. Leptin receptor immunorea(?)tivity in chemically defined target neurons ofthe hypothalamus[J].J Neuresci,1998,18:559.
[8]Collins s, Kuhn CM, Petro AE, et al.Role of leptin in fat regulation [J].Nature,1996,380:6576-677.
[9]Hallas JL. Weight-reducing effects the plasma-protein encoded by the obese gene[J]. Science,1995, 269(5223):269-543.
[10]Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intakes[J]. Nature,2002,418:650-654.
[11]Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse[J]. Biochem Biophys Res Commun,2003,311:915-919.
[12]Alvarez-Bartolome M, Borque M, Martinez-Sartniento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty[J]. Obes Surg,2002,12:32 4-327.
[13]Batterhanl RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36[J]. N Engl J Med,2003,349:941-948.
[14]Pittner RA, MOOre CX, Bhavsar SP, et al. Effects of PYY(3-36)in rodent medels of diabetes and obesity[J]. Intern J Obes,2004,28:963-971.
[15]Sainsbury A. Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in bedy weight regulation revealed in conditional knockout mice[J]. Proe Natl Acad Sci USA,2002,99: 8938-8943.
[16]Cowley MA,Smart JL,Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus[J]. Nature,2001,411:480-484.
[17]Roseberry AG, Liu H, Jackson AC,et al. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice[J].Neuron,2004,41: 711-722.
[1]Leonhardt M, Hrupka B, Langhans W. New approaches in the pharmacological treatment of obesity[J]. Eur J Nutr,1999,38:1-13.
[2]Grundy S. Multifactorial causation of obesity:implication for intervention[J]. Am J Clin Nutr Suppl,1998,67:563S-572S.
[3]Rebuffe-Scrive M, Surwit R, Feinglos M, et al.Regional fat distribution and Metabolism in a new mouse model (C57/BL6) of non-insulin-dependent diabetes mellitus[J].Metabolism,1993,42: 1405-1409.
[4]Portillo MP, Simon E, Garcia-Calonge MA, et al. Effects of high-fat diet on lypolisis in isolated adipocytes from visceral and subcutaneous WAT[J]. Eur J Nutr,1999,38:177-182.
[5]Astrup A, Buemann B, Western P, et al. Christiensen NJ. Obesity is an adaptation to a high-fat diet evidence from a cross-sectional study [J].Am J Clin Nutr,1994,59:350-355.
[6]Billington CJ, Briggs JE, Harker S, et al.Neuropeptide Y in hypothalamic paraventricular nucleus:a center coordinating energy Metabolism[J]. Am J Physiol Regul Integr Comp Physiol,1994, 266:R1765-R1770.
[7]Novin D, Wyrwicka W, Bray GA. Hunger:Basic mechanisms and clinical implications [M]. New York:Raven Press,1976.
[8]Menendez JA, McGregor IS, Healey PA, et al. Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus [J].Brain Res,1990,516:8-14.
[9]Stanley BG, Kyrkouli SE, Lampert S,et al. Neuropeptide Y chronically injected into the hypothalamus:a powerful neurochemical inducer of hyperphagia and obesity[J]. Peptide,1986,7:1189-1192.
[10]Egawa M, Yoshimatsu H, Bray GH. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats[J].Am J Physiol,1991,260:R328-R334.
[11]Zarjevski N,Cusin I, Rohner-Jeanrenaud F, et al. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and Metabolic changes of obesity[J]. Endocrinology,1993,133:1753-1758.
[12]Lambert PD, Wilding JP, al-Dokhayel AA, et al. A role for neuropeptide Y, dynorphin and noradrenaline in the central control of food intake alter food deprivation[J]. Endocrinology,1993,133:29-32.
[13]Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y[J]. Science,1996,274:1704-1707.
[14]Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product[J]. Nature,1995,377:530-532.
[15]Hugo T B, Toom Mizuno, Jason Taylor, et al. Resistance to diet—induced obesity is associated with increased opiomelanocortin mRNA and decreased neuropeptide Y mRNA in the hypothalamus[J]. Brain Res,1999,851:198-203
[16]Levin BE, Richard EK. Defense of differing body weight set points in diet-induced obe se and resistant rats[J]. Am J Physiol,1998,274:r412-419.
[17]Donovan MJ, Paulino G, Raybould HE. Activation of hindbrain neurons in response to gastrointestinal lipid is attenuated by high fat, high energy diets in mice prone to diet-induced obesity[J]. Brain Res,2008,31.
[18]Lu JM, Yao Q, Chen C. Ginseng compounds:an update on their molecular mechanisms and medical applications[J]. Curr Vasc Pharmacol,2009,7(3):293-302.
[19]Chen CF, Chiou WF, Zhang JT.Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium[J].Acta Pharmacol Sin,2008,29(9):1103-1108.
[20]Mollah ML, Kim GS, Moon HK.Antiobesity effects of wild ginseng (Panax ginseng C.A. Meyer) mediated by PPAR-gamma, GLUT4 and LPL in ob/ob mice[J]. Phytother Res,2009,23(2):220-225.
[21]Xie JT, Wang CZ, Ni M.American ginseng berry juice intake reduces blood glucose and body weight in ob/ob mice[J]. J Food Sci,2007,72(8):S590-594.
[22]Xu-Feng Huang, Mei Han, Len H. Storlien.T he level of NPY receptor mRNA expression in diet-induced obese and resistant mice[J].Molecular Brain Research,2003,115:21-28.
[23]Chen X, Dimaggio DA, Han SP, et al. Autore-ceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors[J]. Am J Physiol Heart Circ Physiol,1997,273:H1737-H1744.
[24]Nishimura F, Nishihara M, torii K.et al. Changes in responsiveness to serotonin on rat ventromedial hypothalamic neurons after food deprivation[J]. Physiol Behav,1996,60 (1):7-12.
[25]Morley JE, Levine AS, Gosnell BA, et al. Effect of neuropeptide Y on ingestive behaviors in the rat[J]. Am J Physiol,1987,252:R599-R609.
[26]Adrian TE, Ferri GL, Bacarese-Hamilton AJ,et al. Human distribution and release of a putative new gut hormone, peptide YY[J].Gastroenterology,1985,89:1070-1077.
[27]Lin HC, Chey WY. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs[J].Regul Pept,2003,114:131-135.
[28]Chen CH, Rogers RC.Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus[J]. Am J Physiol Regul Integr Comp Physiol,1997,273:R213-R218.
[29]Xu-Feng Huang, Yinghua Yu,Yulin Li,et al. Ventromedial hypothalamic NPY Y2 receptor in the maintenance of body weight in diet-induced obesity in mice[J]. Neurochem Res,2008,33(9):1881-1888.
[30]leRoux CW,BatterhamRL,AylwinSJB,et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety[J]. Endocrinology,2006,147(1):3-8.
[31]Batterham RL, Cohen MA, Ellis SM, et al.Inhibition of food.intake in obese subjects by peptide YY3-36[J]. N Engl J Med,2003,349:941-948.
[1]The Epidemiology of Hypertension. In:Committee on the Guidelines for the Management of Hypertension from the Japanese Society of Hypertension (editor). Guidelines for the management of hypertension (JSH2009) (in Japanese)[M]. Tokyo:Life Science Publishing,2009:1-7.
[2]Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region[J]. J Hypertens,2003,21:707-716.
[3]Lida M, Ueda K, Okayama A, et al. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese:14 year follow-up of randomly selected population from Japanese——Nippon data 80[J]. J Hum Hypertens,2003,17:851-857.
[4]Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population:the Hisayama study [J]. Stroke,2000,31:2616-2622.
[5]Lewington S, Clarke R, Qizilbash N,et al. Age-specific relevance of usual blood pressure to vascular mortality:a Meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet,2002,360:1903-1913.
[6]Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report[J]. JAMA,2003,289:2560-2572.
[7]Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk:a Meta-analysis of randomized controlled trials[J]. Am J Clin Nutr,2008,88 (1):38-50.
[8]Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [upadated September 2009]. The Cochrane Collaboration,2008. Available from http://www.cochrane-handbook.org. Accessed November 11,2009.
[9]Balk E, Chung M, Chew P, et al. Effects of Soy on Health Outcomes:Evidence Report/Technology Assessment No.126. Rockville, MD:Agency for Healthcare Research and Quality; 2005. AHRQ Publication No.05-E024-2.
[10]Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]? Control Clin Trials,1996,17(1):1-12.
[11]Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials [J]. JAMA,1995,273:408-412.
[12]Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome:cumulative Met a-analyses of randomized, controlled trials[J]. Anesth Analg,1998,86:598-612.
[13]Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans:a Meta-analysis of 11 randomized controlled trials[J]. Am J Clin Nutr,2007,85:1148-1156.
[14]Colacurci N, Chiantera A, Fornaro F, et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women[J]. Menopause,2005,12:299-307.
[15]Garrido A, De la Maza MP, Hirsch S, et al. Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women[J]. Maturitas,2006,54:270-276.
[16]Gleason CE, Carlsson CM, Barnet JH, et al. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women[J]. Age Ageing,2009,38:86-93.
[17]Gonzalez S, Jayagopal V, Kilpatrick ES, et al. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes[J]. Diabetes Care,2007,30:1871-1873.
[18]Han KK, Soares JM, Jr., Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms[J]. Obstet Gynecol,2002,99:389-394.
[19]Hutchins AM, Mclver IE, Johnston CS. Soy isoflavone and ascorbic acid supplementation alone or in combination minimally affect plasma lipid peroxides in healthy postmenopausal women[J]. J Am Diet Assoc,2005,105:1134-1137.
[20]Katz DL, Evans MA, Njike VY, et al. Raloxifene. soy phytoestrogens and endothelial function in postmenopausal women[J]. Climacteric,2007.10:500-507.
[21]Khaodhiar L. Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women[J]. Menopause,2008,15:125-132.
[22]Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women[J]. Am J Cardiol,2000,85:1297-1301.
[23]Squadrito F, Altavilla D, Morabito N, et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women[J]. Atherosclerosis,2002.163:339-347.
[24]Uesugi S, Watanabe S, Ishiwata N, et al. Effects of isoflavone supplements on bone Metabolic markers and climacteric symptoms in Japanese women[J]. Biofactors,2004.22:221-228.
[25]Yao S. Wang Y, Que Y. Effects of Phytoestrogen on serum NO level and cerebral blood flow in postmenopausal women (in Chinese) [J]. Modern Practical Medicine,2007,19:820-821.
[26]Yildiz MF, Kumru S, Godekmerdan A,et al. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women[J]. Int J Gynaecol Obstet,2005,90:128-133.
[27]Zhang L, Pu K. Study of soy isoflavones on improving the large arterial elasticity in patients with Metabolic syndrome (in Chinese) [J]. J Clin Res,2006,23:578-579.
[28]Kenny AM, Mangano KM, Abourizk RH, et al. Soy proteins and isoflavones affect bone mineral density in older women:a randomized controlled trial[J]. Am J Clin Nutr,2009,90 (1):1-9.
[29]He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure:a Meta-analysis of randomized trials. Implications for public health [J]. J Hum Hypertens,2002,16:761-770.
[30]Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure:a Meta-analysis of randomized controlled trials[J]. Hypertension,2003,42:878-884.
[31]Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration[J]. J Nutr,2000,130:2243-2250.
[32]Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis:effect of hormone-replacement therapy on components of the Metabolic syndrome in postmenopausal women[J]. Diabetes Obes Metab,2006,8:538-554.
[33]Walker HA, Dean TS, Sanders TA, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol[J]. Circulation,2001,103:258-262.
[34]Li SH, Liu XX. Bai YY, et al. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women:a Meta-analysis of randomized placebo-controlled trials[J]. Am J Clin Nutr,2010,91:480-486.
[35]Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen[J]. J Clin Invest,1999,103:401-406.
[36]Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause:effects of raloxifene administration[J]. J Clin Endocrinol Metab,2003,88:2135-2140.
[37]Higashi Y, Yoshizumi M. Exercise and endothelial function:role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients[J]. Pharmacol Ther, 2004,102:87-96.
[38]Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta[J]. Biol Pharm Bull,2001,24:351-356.
[39]Morito K, Aomori T, Hirose T, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta(Ⅱ)[J]. Biol Pharm Bull,2002,25:48-52.
[40]Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal Metabolism for bioavailability[J]. Am J Clin Nutr,2002,76:447-453.
[41]Setchell KD. Phytoestrogens:the biochemistry, physiology, and implications for human health of soy isoflavones[J]. Am J Clin Nutr,1998,68:1333S-1346S.
[42]Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake[J]. J Epidemiol, 2000,10:127-135.
[43]Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the Metabolite equol-a clue to the effectiveness of soy and its isoflavones[J]. J Nutr,2002,132:3577-3584.
[1]. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies[J]. Acta-Physiol-Scand,2005 Jan,183(1):13-30.
[2]. Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science,2005(Jan 21),307:426-430.
[3]. Colditz.G.A, Willett.W.C, Rotnitzky A, et al.Weight gain as a risk factor for clinical diabetes mellitus in women[J].Annals of Internal Medicine,1995,122(7):481-486.
[4]. Ohlson L, Larsson B, Svardsudd K, et al.The influence of body fat distribution on the incidence of diabetes mellitus:13.5 years of follow-up of the participants in the study of men bom in 1913[J].D betes,1998,34(10):1055-1058.
[5].漆泓,孙明,周红研.代谢综合征患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系[J].临床内科杂志,2003：20(7)：353-355.
[6]. Kharroubi I, Laurence L, Cardozo AK,et al. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms:role of nuclear factor-kappaB and endoplasmic reticulum stress. [J].Endocrinology,2004,145(11):5087-5096.
[7]. Fantuzzi G. Adipose tissue, adipokines, and inflammation[J]. Allergy Clin Immunol, 2005,115:911-920.
[8]. Samal B, SunY, SteamsG, et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor[J].Mol Cel Biol,1994,14:1431-1437.
[9]. Ognjanovic.S, Bryant-Greenwood. G.D. Pre-B-cell colonyenhancing factor, a novel cytokine of human fetal membranes[J]. Am J. Obstet. Gynecol,2002,187:1051-1058.
[10].Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor[J]. FEBS-Lett,2003,544:74-78.
[11]. Ji A Seo, Eun.S.J, Baek.G.K,et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women[J]. Diabetes research and clinical practice,2008,(79): 108-111.
[12].Jia.S.H, Parodo J, Kapus A,et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis[J]. J. Clin. Invest,2004(113):1318-1327.
[13].C.A. Curat, V. Wegner, C. Sengenes, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 2006,(49):744-747.
[14].T Dogru, A Sonmez, I Tasci, E Bozoglu, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance[J]. Diabetes Research and Clinical Practice,2007, (76):24-29.
[15].Ognjanovic, S, Bryant-Greenwood. G.D. Pre-B-cell colony enhancing factor, a novel cytokine of human fetal membranes[J]. Am.J. Obstet. Gynecol,2002,(187):1051-1058.
[16].Pagano C, Pilon C, Olivieri M, et al.Reduced plasma visfatin/pre B cell colony enhancing factor in obesity is not related to insulin resistance in humans[J].J Clin EndoHnol Metab,2006,91:3165-3170.
[17].J. Berndt, N. Klo"ting, S. Kralisch, et al. Plasma visfatin concentrations and fat depot specific mRNA expression in humans[J], Diabetes,2005, (54):2911-2916.
[18].Chen.M.P, Chung.F.M, Chang.D.M, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2006,(91):295-299.
[19].Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays[J]. Journal of Clinical Endocrinology and Metabolism, 2007,92(12):4783-4791.
[20].Wang P, van-Greevenbroek M.M,Bouwman.F.G,et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile[J]. Pflugers Archiv-European Journal of Physiology, 2007,(454):971-976.
[21].Daniel A, de Luis, Manuel.G.S,et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients[J] Nutrition,2008,24(6):517-521.
[22].Revollo JR, Grimm A A, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells[J]. J Biol Chem,2004. (279):50754-50763.
[2]中国肥胖问题工作组数据总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重指教和腰围切点的研究[J].中华流行病学杂志,2002,23(1)：5-1.
[3]武阳丰,周北凡,廊寿淇,等.我国中年人群超重率和肥胖率的现状及发展趋势[J].中华流行病学杂志,2002,23(1)：11-15.
[4]Kissebah AH, Krakower GR.Regional adiposity and mortality[J]. Physiol Rev,1994,74:761-811.
[5]傅祖植.开展与肥胖相关课题的研究是新世纪的迫切任务[J].中华内分泌代谢杂志,2000,16： 65-66.
[6]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29(2)：153-156.
[7]Levin BE, Richard EK. Defense of differing body weight set points in diet-induced obese and resistant rats[J]. Am J Physiol,1998,274:r412-419.
[8]马健.神经肽Y与肥胖的研究进展[J].心血管病学进展,2004,(增刊)：91-93.
[9]Levin BE, Dunn-Meynell AA, Balkan B, et al.Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats[J]. Am J Physiol,1997,273(2 Pt 2):R725-30.
[10]Mizuno TM, Kleopoulos SP, Bergen HT,et al.Hypothalamic pro-opiomel anocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin[J].Diabetes,1998, 47(4):696.
[11]罗辉.人参皂甙的生物特性及其临床应用研究[J].井冈山学院学报,2006,8：79-82.
[12]Shang WB, Yang Y, Jiang BR, et al.Ginsenoside Rbl promotes adipogenesis in 3T3-L1 cells by enhancing PPARy2 and C/EBPa gene expression[J].Life Sciences,2007,80:618-625.
[13]Kim JH, Young HY, Kang SA. Ginsenoside Rbl as a suppressor in central modulation of feeding in rat[J]. Appetite,2007,49:303.
[1]何晓烨,石风英.高脂饮食在诱导小鼠肥胖及肥胖抵抗中的作用[J].中国临床康复,2002,6：60-61.
[2]孙志,张中成,刘志诚.营养性肥胖动物模型的实验研究[J].中国药理学通报,2002,18(4)：466-467.
[3]王舒然,麻微微,赵丹,等.高脂饮食诱导肥胖与肥胖抵抗动物模型建立[J].中国公共卫生,2007,2(7)：774-775.
[4]Xu-Feng H. Yinghua Y, Yulin L, et al. Ventromedial Hypothalamic NPY Y2 Receptor in the Maintenance of Body Weight in Diet-Induced Obesity in Mice. Neurochem Res[J]. ISSN:1573-6903 (Online).
[5]Richard SS. Shiying W, Anne P, et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice[J].Proc Natl Acad Sci,1998,95:4061-4065.
[6]王重建,杨年红,许明佳.高脂饮食诱导小鼠肥胖易感性差异的研究[J].华中科技大学学报(医学版),2005,1：65.
[7]Levin BE. Metabolic features of diet-induced obesity without hyperphagiain young rats[J]. Am J Physiol,1986,251:433.
[8]Barry EL, Joseph T, Susan H, et al. Resistance to diet-induced obesity:food intake, pancreatic sympathetic tone and insulin[J]. Am J Physiol,1987,252:471-478.
[9]David BW, Carol NB, Deborah LM, et al. Diet obesity in nine inbred mouse strains[J]. Am J Phvsiol,1992,262:1025-1032.
[10]王从容,谭健,杨锡让.高脂饲料诱发小鼠肥胖模型的建立及间接推测体脂法[J].北京体育大学学报,1994,17(3)：20-23.
[11]薛长勇.肥胖和膳食的关系及其措食治疗[J].现代康复,2001,5(9上)：10-11.
[12]FORET JP POSTO WSC.饮食、运动和生活方式变垂在肥胖型糖尿病治疗中的作用[J].现代康复,2001,5(7上)：24-26.
[13]Joseph AM, Yakubu, Lin D,et al. Skeletal musle composition in dietary obesity-susceptible and dietary obesity-resistant rats[J]. Am J Physiol,1992,262:R684-R688.
[14]Sam C, Brent G, Fatima Y, et al. Metabolic differences between obesity-prone and obesity-resistant rats[J]. Am J Physiol,1990,259:R1103-1110.
[15]Thomas JL, Ariel B, Mark D, el al. Plasma growth hormone secretion is impaired in obesity-prone rats before onset of diet-induced obesity[J]. Am J Physiol,1998,275:E6-11.
[16]Beauville M, HarantT I, Crampes F, et al. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine respone[J].Am J Physiol,1992,263:E467-472.
[17]刘庆春,刘晌烨,杜金赞,等.短期内建立营养性肥胖动物模型的实验研究[J].武警医学,2004,15：371-372.
[18]马爽,刘莉,李岩溪,等.肥胖和肥胖抵抗小鼠脂肪组织PPAR7和aP2基因表达的研究[J].卫生研究，2009,3：163-165.
[19]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002.3：153-156.
[1]罗辉.人参皂甙的生物特性及其临床应用的研究[J].井冈山学院学报(自然科学),2006,8：79-82.
[2]丛登云,宋长春,徐景达.西洋参叶中20(S)-人参皂甙Rh2和人参皂甙Rh3的分离和鉴定[J].中国药学杂志,2000，35(2)：82.
[3]Kim JH, Young HY, Kang SA.Ginsenoside Rbl as a suppressor in central modulation of feeding in rat[J]. Appetite,2007,49:303.
[4]Shang WB, Yang Y, Jiang BR, et al.Ginsenoside Rbl promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expression[J]. Life Sciences,2007,80:618-625.
[5]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29(3)：153-156.
[6]Zhang YY, Proenca R, MaffeiM, et al. Positional cloning of themouse obese gene and its human homologue[J].Nature,1994,372:425-432.
[7]刘荣,孙长颢,王舒然,等.饮食诱导肥胖抵抗和饮食诱导肥胖小鼠的对比研究[J].中国公共卫生,2003,19(5)：563-565.
[8]刘荣,孙长颢,李颖,等.饮食诱导肥胖抵抗和肥胖小鼠血中激素水平的比较[J].卫生研究,2003,32(3)：212-214.
[9]Chang S, Graham B, Yakubu F, et al.Metabolic differences between obesity-prone and obesity resistant rats[J].Am J Physiol,1990,259:R11O3.
[10]Terham R L, Cowley M A, Small C J, et al.Gut hormone PYY3-36 physiologicaily inhibits food intake[J].Nature,2002,418:650.
[11]Cowley M A, Smart J L, Rubinstein M,et al.Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus[J]. Nature,2001,411:480.
[12]Akazato M,M urakami N,Date Y, et al. A role for ghrelin in the central regulation of feeding[J]. Nature,2001,409:194.
[13]Pagliassotti MJ,Shahrokhi KA, Hill JO. Skeletal muscle glucose Metabolism in obesity-prone and obesity-resistant rats[J]. Am J Physiol,1993,264:R1224.
[14]Abou M J,Yakubu F,Lin D, et al. Skeletal muscle composition in dietary obesity-susceptible and dietary obesity-resistant rats[J]. Am J Physiol,1992,262:R684.
[15]Weigle D S,Levin B E.Defective dietary induction of uncoupling protein 3 in skeletal muscle of obesity-prone rats[J].Obesity Res,2000,8:385.
[16]Day cp.Non-alcoholic stentohepatisis (NASH):Where are we now and where are we going [J]. Gut,2002,50:585-586.
[17]薛广波.现代疾病预防学[M].北京：人民军医出版社,1996：10.
[18]赵飞,王玉玮,刘心洁,等.高脂诱导肥胖与肥胖抵抗小鼠血糖、血脂、瘦素及胰岛素敏感性比较[J].中国儿童保健杂志,2004,12(6)：517-519.
[19]施万英,徐甲芬,姚兴家,等.高脂饮食对肥胖倾向和肥胖抵抗小鼠血清脂质和TNF-α水平的影响[J].中国医科大学学报,33(4)：330-332.
[20]Dobrian AD, Davies IJ, Prewitt RL, et al. Development of hypertension in a rat model of diet-induced obesity[J]. Hypertension,2000,35(4):1009-1015.
[1]刘荣.肥胖抵抗现象的研究概况[J].国外医学卫生学分册,2002,29：153-156.
[2]张贝,李成江.PYY与肥胖[J].国外医学内分泌学分册,2005,25(suppl)：6-8.
[3]Batterham RL,Small CJ,Cowley MA,et al.Gut hormone PYY(3-36) physiologically inhibit food intake[J].Nature,2002,418:650-654.
[4]Sainsbury A, Schwarzer C, Couzens M,et al.Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice[J].Proc Natl Acad Sci USA,2002,99(13): 8938-8943.
[5]Batterham RL, Cowley MA, Small CJ, et al.Gut hormone PYY(3-36) physiologically inhibits food intake [J].Nature,2002,418(6898):650-4.
[6]Baskin DG, Breininger JF, Schartz MW. Leptin receptor mRNA identifiers a sub-population of neuropeptide Y neurons activated by fasting in rAt hypothatamus[J].Diabetes,1999,48(4):828-833.
[7]Hakasson ML. Leptin receptor immunorea(?)tivity in chemically defined target neurons ofthe hypothalamus[J].J Neuresci,1998,18:559.
[8]Collins s, Kuhn CM, Petro AE, et al.Role of leptin in fat regulation [J].Nature,1996,380:6576-677.
[9]Hallas JL. Weight-reducing effects the plasma-protein encoded by the obese gene[J]. Science,1995, 269(5223):269-543.
[10]Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intakes[J]. Nature,2002,418:650-654.
[11]Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse[J]. Biochem Biophys Res Commun,2003,311:915-919.
[12]Alvarez-Bartolome M, Borque M, Martinez-Sartniento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty[J]. Obes Surg,2002,12:32 4-327.
[13]Batterhanl RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36[J]. N Engl J Med,2003,349:941-948.
[14]Pittner RA, MOOre CX, Bhavsar SP, et al. Effects of PYY(3-36)in rodent medels of diabetes and obesity[J]. Intern J Obes,2004,28:963-971.
[15]Sainsbury A. Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in bedy weight regulation revealed in conditional knockout mice[J]. Proe Natl Acad Sci USA,2002,99: 8938-8943.
[16]Cowley MA,Smart JL,Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus[J]. Nature,2001,411:480-484.
[17]Roseberry AG, Liu H, Jackson AC,et al. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice[J].Neuron,2004,41: 711-722.
[1]Leonhardt M, Hrupka B, Langhans W. New approaches in the pharmacological treatment of obesity[J]. Eur J Nutr,1999,38:1-13.
[2]Grundy S. Multifactorial causation of obesity:implication for intervention[J]. Am J Clin Nutr Suppl,1998,67:563S-572S.
[3]Rebuffe-Scrive M, Surwit R, Feinglos M, et al.Regional fat distribution and Metabolism in a new mouse model (C57/BL6) of non-insulin-dependent diabetes mellitus[J].Metabolism,1993,42: 1405-1409.
[4]Portillo MP, Simon E, Garcia-Calonge MA, et al. Effects of high-fat diet on lypolisis in isolated adipocytes from visceral and subcutaneous WAT[J]. Eur J Nutr,1999,38:177-182.
[5]Astrup A, Buemann B, Western P, et al. Christiensen NJ. Obesity is an adaptation to a high-fat diet evidence from a cross-sectional study [J].Am J Clin Nutr,1994,59:350-355.
[6]Billington CJ, Briggs JE, Harker S, et al.Neuropeptide Y in hypothalamic paraventricular nucleus:a center coordinating energy Metabolism[J]. Am J Physiol Regul Integr Comp Physiol,1994, 266:R1765-R1770.
[7]Novin D, Wyrwicka W, Bray GA. Hunger:Basic mechanisms and clinical implications [M]. New York:Raven Press,1976.
[8]Menendez JA, McGregor IS, Healey PA, et al. Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus [J].Brain Res,1990,516:8-14.
[9]Stanley BG, Kyrkouli SE, Lampert S,et al. Neuropeptide Y chronically injected into the hypothalamus:a powerful neurochemical inducer of hyperphagia and obesity[J]. Peptide,1986,7:1189-1192.
[10]Egawa M, Yoshimatsu H, Bray GH. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats[J].Am J Physiol,1991,260:R328-R334.
[11]Zarjevski N,Cusin I, Rohner-Jeanrenaud F, et al. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and Metabolic changes of obesity[J]. Endocrinology,1993,133:1753-1758.
[12]Lambert PD, Wilding JP, al-Dokhayel AA, et al. A role for neuropeptide Y, dynorphin and noradrenaline in the central control of food intake alter food deprivation[J]. Endocrinology,1993,133:29-32.
[13]Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y[J]. Science,1996,274:1704-1707.
[14]Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product[J]. Nature,1995,377:530-532.
[15]Hugo T B, Toom Mizuno, Jason Taylor, et al. Resistance to diet—induced obesity is associated with increased opiomelanocortin mRNA and decreased neuropeptide Y mRNA in the hypothalamus[J]. Brain Res,1999,851:198-203
[16]Levin BE, Richard EK. Defense of differing body weight set points in diet-induced obe se and resistant rats[J]. Am J Physiol,1998,274:r412-419.
[17]Donovan MJ, Paulino G, Raybould HE. Activation of hindbrain neurons in response to gastrointestinal lipid is attenuated by high fat, high energy diets in mice prone to diet-induced obesity[J]. Brain Res,2008,31.
[18]Lu JM, Yao Q, Chen C. Ginseng compounds:an update on their molecular mechanisms and medical applications[J]. Curr Vasc Pharmacol,2009,7(3):293-302.
[19]Chen CF, Chiou WF, Zhang JT.Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium[J].Acta Pharmacol Sin,2008,29(9):1103-1108.
[20]Mollah ML, Kim GS, Moon HK.Antiobesity effects of wild ginseng (Panax ginseng C.A. Meyer) mediated by PPAR-gamma, GLUT4 and LPL in ob/ob mice[J]. Phytother Res,2009,23(2):220-225.
[21]Xie JT, Wang CZ, Ni M.American ginseng berry juice intake reduces blood glucose and body weight in ob/ob mice[J]. J Food Sci,2007,72(8):S590-594.
[22]Xu-Feng Huang, Mei Han, Len H. Storlien.T he level of NPY receptor mRNA expression in diet-induced obese and resistant mice[J].Molecular Brain Research,2003,115:21-28.
[23]Chen X, Dimaggio DA, Han SP, et al. Autore-ceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors[J]. Am J Physiol Heart Circ Physiol,1997,273:H1737-H1744.
[24]Nishimura F, Nishihara M, torii K.et al. Changes in responsiveness to serotonin on rat ventromedial hypothalamic neurons after food deprivation[J]. Physiol Behav,1996,60 (1):7-12.
[25]Morley JE, Levine AS, Gosnell BA, et al. Effect of neuropeptide Y on ingestive behaviors in the rat[J]. Am J Physiol,1987,252:R599-R609.
[26]Adrian TE, Ferri GL, Bacarese-Hamilton AJ,et al. Human distribution and release of a putative new gut hormone, peptide YY[J].Gastroenterology,1985,89:1070-1077.
[27]Lin HC, Chey WY. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs[J].Regul Pept,2003,114:131-135.
[28]Chen CH, Rogers RC.Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus[J]. Am J Physiol Regul Integr Comp Physiol,1997,273:R213-R218.
[29]Xu-Feng Huang, Yinghua Yu,Yulin Li,et al. Ventromedial hypothalamic NPY Y2 receptor in the maintenance of body weight in diet-induced obesity in mice[J]. Neurochem Res,2008,33(9):1881-1888.
[30]leRoux CW,BatterhamRL,AylwinSJB,et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety[J]. Endocrinology,2006,147(1):3-8.
[31]Batterham RL, Cohen MA, Ellis SM, et al.Inhibition of food.intake in obese subjects by peptide YY3-36[J]. N Engl J Med,2003,349:941-948.
[1]The Epidemiology of Hypertension. In:Committee on the Guidelines for the Management of Hypertension from the Japanese Society of Hypertension (editor). Guidelines for the management of hypertension (JSH2009) (in Japanese)[M]. Tokyo:Life Science Publishing,2009:1-7.
[2]Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region[J]. J Hypertens,2003,21:707-716.
[3]Lida M, Ueda K, Okayama A, et al. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese:14 year follow-up of randomly selected population from Japanese——Nippon data 80[J]. J Hum Hypertens,2003,17:851-857.
[4]Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population:the Hisayama study [J]. Stroke,2000,31:2616-2622.
[5]Lewington S, Clarke R, Qizilbash N,et al. Age-specific relevance of usual blood pressure to vascular mortality:a Meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet,2002,360:1903-1913.
[6]Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report[J]. JAMA,2003,289:2560-2572.
[7]Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk:a Meta-analysis of randomized controlled trials[J]. Am J Clin Nutr,2008,88 (1):38-50.
[8]Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [upadated September 2009]. The Cochrane Collaboration,2008. Available from http://www.cochrane-handbook.org. Accessed November 11,2009.
[9]Balk E, Chung M, Chew P, et al. Effects of Soy on Health Outcomes:Evidence Report/Technology Assessment No.126. Rockville, MD:Agency for Healthcare Research and Quality; 2005. AHRQ Publication No.05-E024-2.
[10]Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]? Control Clin Trials,1996,17(1):1-12.
[11]Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials [J]. JAMA,1995,273:408-412.
[12]Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome:cumulative Met a-analyses of randomized, controlled trials[J]. Anesth Analg,1998,86:598-612.
[13]Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans:a Meta-analysis of 11 randomized controlled trials[J]. Am J Clin Nutr,2007,85:1148-1156.
[14]Colacurci N, Chiantera A, Fornaro F, et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women[J]. Menopause,2005,12:299-307.
[15]Garrido A, De la Maza MP, Hirsch S, et al. Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women[J]. Maturitas,2006,54:270-276.
[16]Gleason CE, Carlsson CM, Barnet JH, et al. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women[J]. Age Ageing,2009,38:86-93.
[17]Gonzalez S, Jayagopal V, Kilpatrick ES, et al. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes[J]. Diabetes Care,2007,30:1871-1873.
[18]Han KK, Soares JM, Jr., Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms[J]. Obstet Gynecol,2002,99:389-394.
[19]Hutchins AM, Mclver IE, Johnston CS. Soy isoflavone and ascorbic acid supplementation alone or in combination minimally affect plasma lipid peroxides in healthy postmenopausal women[J]. J Am Diet Assoc,2005,105:1134-1137.
[20]Katz DL, Evans MA, Njike VY, et al. Raloxifene. soy phytoestrogens and endothelial function in postmenopausal women[J]. Climacteric,2007.10:500-507.
[21]Khaodhiar L. Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women[J]. Menopause,2008,15:125-132.
[22]Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women[J]. Am J Cardiol,2000,85:1297-1301.
[23]Squadrito F, Altavilla D, Morabito N, et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women[J]. Atherosclerosis,2002.163:339-347.
[24]Uesugi S, Watanabe S, Ishiwata N, et al. Effects of isoflavone supplements on bone Metabolic markers and climacteric symptoms in Japanese women[J]. Biofactors,2004.22:221-228.
[25]Yao S. Wang Y, Que Y. Effects of Phytoestrogen on serum NO level and cerebral blood flow in postmenopausal women (in Chinese) [J]. Modern Practical Medicine,2007,19:820-821.
[26]Yildiz MF, Kumru S, Godekmerdan A,et al. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women[J]. Int J Gynaecol Obstet,2005,90:128-133.
[27]Zhang L, Pu K. Study of soy isoflavones on improving the large arterial elasticity in patients with Metabolic syndrome (in Chinese) [J]. J Clin Res,2006,23:578-579.
[28]Kenny AM, Mangano KM, Abourizk RH, et al. Soy proteins and isoflavones affect bone mineral density in older women:a randomized controlled trial[J]. Am J Clin Nutr,2009,90 (1):1-9.
[29]He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure:a Meta-analysis of randomized trials. Implications for public health [J]. J Hum Hypertens,2002,16:761-770.
[30]Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure:a Meta-analysis of randomized controlled trials[J]. Hypertension,2003,42:878-884.
[31]Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration[J]. J Nutr,2000,130:2243-2250.
[32]Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis:effect of hormone-replacement therapy on components of the Metabolic syndrome in postmenopausal women[J]. Diabetes Obes Metab,2006,8:538-554.
[33]Walker HA, Dean TS, Sanders TA, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol[J]. Circulation,2001,103:258-262.
[34]Li SH, Liu XX. Bai YY, et al. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women:a Meta-analysis of randomized placebo-controlled trials[J]. Am J Clin Nutr,2010,91:480-486.
[35]Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen[J]. J Clin Invest,1999,103:401-406.
[36]Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause:effects of raloxifene administration[J]. J Clin Endocrinol Metab,2003,88:2135-2140.
[37]Higashi Y, Yoshizumi M. Exercise and endothelial function:role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients[J]. Pharmacol Ther, 2004,102:87-96.
[38]Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta[J]. Biol Pharm Bull,2001,24:351-356.
[39]Morito K, Aomori T, Hirose T, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta(Ⅱ)[J]. Biol Pharm Bull,2002,25:48-52.
[40]Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal Metabolism for bioavailability[J]. Am J Clin Nutr,2002,76:447-453.
[41]Setchell KD. Phytoestrogens:the biochemistry, physiology, and implications for human health of soy isoflavones[J]. Am J Clin Nutr,1998,68:1333S-1346S.
[42]Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake[J]. J Epidemiol, 2000,10:127-135.
[43]Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the Metabolite equol-a clue to the effectiveness of soy and its isoflavones[J]. J Nutr,2002,132:3577-3584.
[1]. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies[J]. Acta-Physiol-Scand,2005 Jan,183(1):13-30.
[2]. Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science,2005(Jan 21),307:426-430.
[3]. Colditz.G.A, Willett.W.C, Rotnitzky A, et al.Weight gain as a risk factor for clinical diabetes mellitus in women[J].Annals of Internal Medicine,1995,122(7):481-486.
[4]. Ohlson L, Larsson B, Svardsudd K, et al.The influence of body fat distribution on the incidence of diabetes mellitus:13.5 years of follow-up of the participants in the study of men bom in 1913[J].D betes,1998,34(10):1055-1058.
[5].漆泓,孙明,周红研.代谢综合征患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系[J].临床内科杂志,2003：20(7)：353-355.
[6]. Kharroubi I, Laurence L, Cardozo AK,et al. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms:role of nuclear factor-kappaB and endoplasmic reticulum stress. [J].Endocrinology,2004,145(11):5087-5096.
[7]. Fantuzzi G. Adipose tissue, adipokines, and inflammation[J]. Allergy Clin Immunol, 2005,115:911-920.
[8]. Samal B, SunY, SteamsG, et al.Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor[J].Mol Cel Biol,1994,14:1431-1437.
[9]. Ognjanovic.S, Bryant-Greenwood. G.D. Pre-B-cell colonyenhancing factor, a novel cytokine of human fetal membranes[J]. Am J. Obstet. Gynecol,2002,187:1051-1058.
[10].Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor[J]. FEBS-Lett,2003,544:74-78.
[11]. Ji A Seo, Eun.S.J, Baek.G.K,et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women[J]. Diabetes research and clinical practice,2008,(79): 108-111.
[12].Jia.S.H, Parodo J, Kapus A,et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis[J]. J. Clin. Invest,2004(113):1318-1327.
[13].C.A. Curat, V. Wegner, C. Sengenes, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 2006,(49):744-747.
[14].T Dogru, A Sonmez, I Tasci, E Bozoglu, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance[J]. Diabetes Research and Clinical Practice,2007, (76):24-29.
[15].Ognjanovic, S, Bryant-Greenwood. G.D. Pre-B-cell colony enhancing factor, a novel cytokine of human fetal membranes[J]. Am.J. Obstet. Gynecol,2002,(187):1051-1058.
[16].Pagano C, Pilon C, Olivieri M, et al.Reduced plasma visfatin/pre B cell colony enhancing factor in obesity is not related to insulin resistance in humans[J].J Clin EndoHnol Metab,2006,91:3165-3170.
[17].J. Berndt, N. Klo"ting, S. Kralisch, et al. Plasma visfatin concentrations and fat depot specific mRNA expression in humans[J], Diabetes,2005, (54):2911-2916.
[18].Chen.M.P, Chung.F.M, Chang.D.M, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2006,(91):295-299.
[19].Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays[J]. Journal of Clinical Endocrinology and Metabolism, 2007,92(12):4783-4791.
[20].Wang P, van-Greevenbroek M.M,Bouwman.F.G,et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile[J]. Pflugers Archiv-European Journal of Physiology, 2007,(454):971-976.
[21].Daniel A, de Luis, Manuel.G.S,et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients[J] Nutrition,2008,24(6):517-521.
[22].Revollo JR, Grimm A A, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells[J]. J Biol Chem,2004. (279):50754-50763.